Company Presentation

Investment highlights

  • A "first-in-class" small molecule therapeutic with a unique mechanism of action
  • Anti-cancer activity demonstrated across a range of cancers in prior US National Cancer Institute (NCI)-sponsored clinical trials
  • Promising interim outcomes data from ongoing refractory GBM clinical trial
  • Phase II/III registration trial of VAL-083 in refractory GBM in 2016
  • Orphan drug designation in USA and EU
  • Newly allowed patent claims provide intellectual property protection through 2032
  • Pipeline expansion opportunities in high value oncology markets
  • Experienced Team with History of Success
  • Proven Business Model